Teladoc Health (TDOC) Earnings Date & Reports

Key Takeaways

• Third Quarter 2026 revenue came in at $605.1 million, down 3% year-over-year but near the upper end of the company's guidance range.
• Net loss narrowed to $26.9 million, or $0.15 per share, improving from a $49.5 million loss a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 14% to $79.4 million, above guidance.
• Integrated Care revenue grew 2% to $398.5 million, while BetterHelp revenue fell 13% to $206.6 million.
• Management issued full-year 2026 revenue guidance of $2,395 million to $2,441 million and free cash flow guidance of $135 million to $165 million.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional Tickeron pages dedicated to TDOC.
• Investors seeking automated market insights can also explore Trending AI Robots.

Earnings Context and Why It Matters

Teladoc Health's Third Quarter 2026 report offers a critical read on whether the company's two-pronged strategy is working. The Integrated Care segment, serving health plans and employers, has been the engine of stability and margin expansion. In contrast, BetterHelp, the direct-to-consumer mental health business, is navigating a deliberate shift away from cash-pay users toward insurance-covered services. That transition has pressured top-line growth even as it improves the long-term quality of revenue. With the company still reporting net losses, investors are watching closely for signs that adjusted profitability and free cash flow can continue improving while the BetterHelp mix shift plays out. This quarter's results provide fresh evidence on both fronts.

Reported Results

Teladoc Health reported Third Quarter 2026 revenue of $605.1 million, a 3% decline from $626.4 million in the year-ago period but near the upper end of management's guidance. Net loss totaled $26.9 million, or $0.15 per share, versus a net loss of $49.5 million, or $0.28 per share, a year earlier.

Adjusted EBITDA increased 14% to $79.4 million, exceeding the company's guidance range. Within the segments, Integrated Care revenue grew 2% to $398.5 million with an adjusted EBITDA margin of 18.8%, while BetterHelp revenue declined 13% to $206.6 million with an adjusted EBITDA margin of 2.2%.

Cash flow from operations was $106.5 million, and free cash flow reached $75.9 million. For the full year 2026, management guided to revenue of $2,395 million to $2,441 million, adjusted EBITDA of $277 million to $303 million, and net loss per share of $0.95 to $0.75.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are tracking names like Teladoc Health, the AI Screener can help you identify comparable opportunities across the healthcare and technology landscape.

Market Reaction and Investor Sentiment

Shares of Teladoc Health closed higher on the day of the report, with the stock gaining more than 6% in regular trading and rising further in after-hours action. The positive reaction reflects investor relief that consolidated revenue landed near the top of guidance while adjusted EBITDA came in above the expected range. Commentary from CEO Chuck Divita emphasized "solid execution across our two segments," including better-than-expected insurance revenue at BetterHelp and encouraging progress expanding provider capacity. Still, the persistent decline in BetterHelp's cash-pay user base remains a focal point for sentiment, and investors are likely to weigh the improving margin profile against ongoing top-line contraction in that segment.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape how investors interpret Teladoc Health's trajectory following this report. First is the BetterHelp transition from cash-pay to insurance-covered services. Management reported that insurance revenue exceeded expectations this quarter, but the key question is whether provider capacity can scale quickly enough to convert rising demand into billable sessions without further revenue erosion.

Second, Integrated Care momentum matters. The segment's 2% revenue growth and 18.8% adjusted EBITDA margin suggest the core business is delivering on its profitability goals. Investors should monitor U.S. Integrated Care membership levels, which management guided to a range of 99.5 million to 100.5 million for year-end.

Finally, cost discipline and free cash flow will remain central. The company's full-year free cash flow guidance of $135 million to $165 million underscores management's focus on generating cash even while reporting net losses tied to intangible amortization and stock-based compensation. Execution against that free cash flow target, along with the rollout of initiatives such as Teladoc One and AI-enabled solutions, will be the key catalysts to watch in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations